Ketamine assisted psychotherapy (KAP) is a therapeutic approach that combines the bio-medical benefits of ketamine with its psychedelic properties to facilitate a unique treatment process. This approach is supported by a growing body of research demonstrating the effectiveness of psychedelic agents such as MDMA, psilocybin, and ketamine for the treatment of conditions such a depression, addiction, PTSD, chronic pain, and end of life distress. Ketamine is currently available for clinical use while MDMA and psilocybin are still progressing through the FDA approval process.
